AAP
GANX icon

Arax Advisory Partners’s Gain Therapeutics GANX Stock Holding History

Arax Advisory Partners’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.45K Buy
+1,700
New +$3.13K ﹤0.01% 4686
2025
Q4 		– Sell
-3,250
Closed -$5.75K – 4256
2025
Q3 		$5.75K Buy
3,250
+750
+30% +$1.26K ﹤0.01% 2826
2025
Q2 		$4.5K Hold
2,500
– – ﹤0.01% 2293
2025
Q1 		$4.78K Buy
+2,500
New +$5.54K ﹤0.01% 1797

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Arax Advisory Partners's GANX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Gain Therapeutics (GANX) in Q2 2026: 1,700 shares worth $3.45K. The stake represents ﹤0.01% of the portfolio and ranks #4686 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in GANX as recently as Q3 2025.

Arax Advisory Partners first reported a position in GANX in Q1 2025 and has held it in 4 quarters since. The position peaked at $5.75K in Q3 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Arax Advisory Partners held 1,700 shares of Gain Therapeutics worth $3.45K as of Q2 2026.
  • Gain Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4686 holding.
  • Arax Advisory Partners first reported a position in Gain Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Gain Therapeutics position peaked at $5.75K in Q3 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.